Form 4: Elicio Therapeutics CEO Acquires Stock Options
SEC Form 4 Filing
Robert Connelly, CEO of Elicio Therapeutics, reports the acquisition of stock options.
Summary
- Robert Connelly, the CEO, President, and Director of Elicio Therapeutics, Inc., filed a Form 4 on October 2, 2024.
- The report details the acquisition of 91,600 stock options with an exercise price of $5.03 on September 30, 2024.
- These options vest in two tranches: 50% on September 30, 2025, and the remaining 50% on September 30, 2026, contingent upon continued service to the company.
- Following the transaction, Connelly directly owns 91,600 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock options is generally viewed as a positive sign, indicating confidence in the company's future.
Positives
- The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Stakeholder Impact
- The stock option grant could positively impact shareholders by aligning management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of the stock option grant and transaction. |
| 09/30/2025 | First vesting date for 50% of the stock options. |
| 09/30/2026 | Second vesting date for the remaining 50% of the stock options. |
| 09/30/2034 | Expiration date of the stock options. |
| 10/02/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.